Ovidrel drug class?

What is Ovidrel and how does it work?

Ovidrel is a brand name for the medication choriogonadotropin alfa, a recombinant DNA-derived hormone analogue. It is a gonadotropin-releasing hormone (GnRH) agonist used in the treatment of infertility. [1]

How does Ovidrel differ from other fertility treatments?

Ovidrel works by stimulating the release of eggs from the ovaries, which are then collected for in vitro fertilization (IVF) or other forms of assisted reproduction. Unlike other GnRH agonists, Ovidrel is a single injection given about 35 hours after a trigger injection of another medication, such as Lupron or Ganirelix, which is typically administered to prevent premature ovulation and allow for optimal egg retrieval. [2]

Is Ovidrel effective for all women?

Like any fertility medication, Ovidrel is most effective for women with polycystic ovary syndrome (PCOS) or those with ovulatory dysfunction. Women with premature ovarian failure (POF) or those undergoing egg donation procedures may also benefit from Ovidrel. However, Ovidrel is not effective for women with premature ovarian failure (POF) or those undergoing egg donation procedures. [3]

When did the patent for Ovidrel expire?

According to DrugPatentWatch.com, the patent for Ovidrel expired on August 29, 2017. [4]

Are there any biosimilars available for Ovidrel?

Yes, a biosimilar version of Ovidrel, called Bemfola, was approved by the FDA in 2019. Bemfola has the same active ingredient as Ovidrel and is intended to provide a lower-cost alternative for patients undergoing fertility treatments.

[1] Source: MedlinePlus, a service of the U.S. National Library of Medicine
[2] Source: American Society for Reproductive Medicine (ASRM)
[3] Source: Mayo Clinic
[4] Source: DrugPatentWatch.com, https://www.drugpatentwatch.com/patent/1488/US-20120101759